Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications

Febrile Seizures and Childhood Epilepsy Syndromes

Seizures are among the most frequent neurological emergencies encountered in pediatric practice. A critical competency in pediatric medicine is distinguishing benign, age-limited paroxysmal events—such as simple febrile seizures—from complex febrile seizures, life-threatening CNS infections, and catastrophic epileptic encephalopathies. Accurate syndrome recognition guides appropriate neuroimaging, electroencephalography (EEG), targeted antiseizure medication (ASM) selection, and prognostic counseling.

---

Febrile Seizures: Epidemiology and Diagnostic Criteria

Febrile seizures are the most common convulsive disorder of early childhood, affecting 2% to 5% of children in Europe and North America, with higher rates (up to 8–10%) reported in Japan. They reflect age-dependent cerebral vulnerability to rapid temperature elevation in an immature, developing brain with heightened neuronal excitability and an imbalance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmission.

Consensus Diagnostic Criteria (AAP and European Guidelines)

A febrile seizure is formally diagnosed only when all five criteria are met:

1. Age: Child is between 6 months and 60 months (5 years) of age (peak incidence occurs between 12 and 18 months).
2. Fever: Elevated core body temperature ≥38.0°C (100.4°F) present before, during, or immediately following the seizure.
3. Absence of Intracranial Infection: Definite exclusion of meningitis, encephalitis, brain abscess, or other CNS infection.
4. Absence of Acute Metabolic Derangement: No systemic metabolic disturbance capable of provoking seizures (e.g., hypoglycemia, severe hyponatremia, hypocalcemia).
5. Absence of Prior Afebrile Seizures: No preceding history of unprovoked (afebrile) epileptic seizures.

---

Simple vs. Complex Febrile Seizures

Febrile seizures are dichotomized into simple (benign) and complex (atypical) presentations. This distinction dictates the diagnostic workup, risk of recurrence, and likelihood of later unprovoked epilepsy.

Recurrence Risk Stratification

Following a first febrile seizure, the overall risk of experiencing a recurrent febrile seizure is approximately 30% to 35%. Four primary risk factors predict recurrence:

• Young age at onset (<12–18 months): Strongest single predictor (recurrence risk exceeds 50%).
• Lower degree of fever: Seizure occurring at a core temperature <38.5°C.
• Shorter duration of fever: Seizure occurring <1 hour after the onset of recognized fever.
• Family history: First-degree relative with a history of febrile seizures.

Risk of Developing Subsequent Afebrile Epilepsy

While simple febrile seizures carry a minimal risk of subsequent epilepsy (1–2%), specific risk factors elevate this hazard:

1. Pre-existing neurodevelopmental abnormality (e.g., cerebral palsy, global developmental delay, microcephaly).
2. Complex febrile seizure features (especially focal semiology or febrile status epilepticus).
3. Family history of afebrile epilepsy in a first-degree relative.
4. Onset before 12 months of age.

If a child has no risk factors, the risk of epilepsy is ~1%. If one risk factor is present, the risk is ~2–3%. With two or more risk factors, the risk rises to 5% to 10%.

---

Emergency Management and Parental Guidance

                       [Child having an active seizure]
                                    |
[Time seizure; protect airway; lateral position; nothing in mouth]
                                    |
                    [At 5 minutes: give rescue medicine]
          [Buccal midazolam 0.5 mg/kg (max 10 mg) OR rectal diazepam 0.5 mg/kg]
                                    |
          [If ongoing 5–10 minutes later: repeat benzodiazepine once]
              [Count doses already given; seek emergency help]
                                    |
              [Persistent seizure after 2 benzodiazepine doses]
             [IV second-line medicine with airway/respiratory support]

Acute Resuscitation Protocol

• Immediate First Aid: Place the child in the lateral recovery position to prevent aspiration. Loosen tight clothing around the neck. Do not restrain the child and never insert fingers or utensils into the mouth.
• Timing: Most febrile seizures terminate spontaneously within 2 to 3 minutes. If the seizure duration reaches 5 minutes, active medical intervention is mandatory to prevent progression to status epilepticus.
• First-Line Rescue Medication:
  • Buccal Midazolam: 0.5 mg/kg (maximum single dose 10 mg). Administered between the lower gum and cheek; preferred in Europe due to rapid transmucosal absorption, ease of administration, and superior efficacy compared to rectal diazepam.
  • Rectal Diazepam: 0.5 mg/kg (maximum single dose 10 mg; 0.5 mg/kg for age <2 yr, 0.3–0.5 mg/kg for older children).
  • If seizures continue, seek emergency help and repeat the benzodiazepine once after 5–10 minutes, counting any pre-hospital doses. After 2 doses, ongoing seizures require IV second-line treatment: levetiracetam 40–60 mg/kg, phenytoin 20 mg/kg or fosphenytoin 20 mg PE/kg, with cardiorespiratory monitoring and airway support as needed.

Evidence-Based Parental Counseling on Antipyretics

• Symptomatic Relief Only: Antipyretics such as paracetamol (acetaminophen) 15 mg/kg every 4–6 hours and ibuprofen 10 mg/kg every 6–8 hours alleviate discomfort, reduce metabolic demand, and treat systemic pain.
• Inefficacy for Seizure Prevention: Multiple randomized, placebo-controlled clinical trials have conclusively demonstrated that antipyretics DO NOT prevent the occurrence or recurrence of febrile seizures. Febrile seizures often occur during the initial precipitous rise in temperature before parents recognize the child is febrile. Counsel parents not to administer round-the-clock antipyretics aggressively under the false assumption that it prevents seizures.

---

Childhood Epilepsy Syndromes: Electroclinical Hallmarks

The International League Against Epilepsy (ILAE) classifies pediatric epilepsies into distinct electroclinical syndromes based on age of onset, seizure semiology, and pathognomonic EEG patterns.

+---------------------------------------------------------------------------------------------------------+
|                                 MAJOR CHILDHOOD EPILEPSY SYNDROMES                                      |
+------------------------------------+-----------------------------------+--------------------------------+
| Syndrome & Typical Onset           | Clinical Semiology & EEG Hallmark | First-Line Therapy & Alerts    |
+------------------------------------+-----------------------------------+--------------------------------+
| Childhood Absence Epilepsy (CAE)   | Staring spells (5-15 s), eye blink| Ethosuximide (first-line)      |
| Onset: 4 to 10 years               | 3 Hz generalized spike-and-wave   | CONTRAINDICATED: Carbamazepine |
+------------------------------------+-----------------------------------+--------------------------------+
| Infantile Spasms (West Syndrome)   | Clusters of sudden flexion spasms | High-dose Prednisolone or ACTH |
| Onset: 3 to 12 months              | Hypsarrhythmia on interictal EEG  | Vigabatrin (first-line in TSC) |
+------------------------------------+-----------------------------------+--------------------------------+
| Self-Limited Centrotemporal Spikes | Nocturnal hemifacial twitching    | Often no medication needed;    |
| (Benign Rolandic / SeLECTS)        | Centrotemporal broad sharp waves  | Levetiracetam or Sulthiame     |
| Onset: 3 to 12 years               | Activated by non-REM sleep        | Spontaneous adolescent remission |
+------------------------------------+-----------------------------------+--------------------------------+
| Juvenile Myoclonic Epilepsy (JME)  | Morning myoclonic arm jerks       | Levetiracetam or Valproate     |
| Onset: 12 to 18 years              | 4 to 6 Hz polyspike-and-wave      | VALPROATE TERATOGENIC WARNING  |
+------------------------------------+-----------------------------------+--------------------------------+

1. Childhood Absence Epilepsy (CAE)

• Epidemiology and Clinical Picture: Onset between 4 and 10 years (peak 5–7 years), with a female predominance (60–70%). Manifests as frequent, brief (5 to 15 seconds) episodes of profound behavioral arrest, blank staring, and unresponsiveness, occurring dozens to hundreds of times daily. May be accompanied by subtle automatisms (eyelid fluttering, mouth twitching, lip smacking). Episodes have an abrupt onset and abrupt termination with immediate recovery of full consciousness, without post-ictal confusion or fatigue.
• Clinic Provocation: Readily provoked in the examination room by having the child perform hyperventilation for 3 minutes (e.g., blowing on a pinwheel or piece of paper).
• EEG Hallmark: Symmetrical, synchronous, bilateral 3 Hz (2.5 to 3.5 Hz) generalized spike-and-wave discharges that arise abruptly from a normal background.
• Pharmacotherapy:
  • First-Line: Ethosuximide (T-type voltage-gated calcium channel blocker in thalamocortical relay neurons). Demonstrates equal efficacy to valproate in terminating absence seizures and normalizing EEG, but with significantly fewer attentional, cognitive, and metabolic adverse effects.
  • Second-Line: Sodium Valproate or Lamotrigine.

  • Warning

  • Contraindicated Medications: Sodium channel blockers (Carbamazepine, Oxcarbazepine, Phenytoin) and GABAergic inhibitors (Vigabatrin, Tiagabine) aggravate absence seizures and can precipitate absence status epilepticus.

2. Infantile Spasms (West Syndrome)

• Epidemiology: Severe epileptic encephalopathy presenting between 3 and 12 months of age (peak 4–7 months), affecting approximately 1 in 2,500 infants.
• The Diagnostic Triad:
  1. Epileptic Spasms: Sudden, brief (0.5 to 2 seconds) muscle contractions involving the neck, trunk, and limbs. They present as flexor spasms ("jack-knife" forward bending), extensor spasms (head and trunk extension with arm abduction), or mixed flexor-extensor spasms. Crucially, spasms occur in clusters of 20 to 100+ individual spasms, typically upon waking from sleep or during drowsiness.
  2. Hypsarrhythmia on EEG: Interictal EEG shows a high-voltage, chaotic, disorganized background with continuous, multifocal spike and slow-wave discharges, lacking interhemispheric synchrony, punctuated by sudden voltage attenuation (electrodecremental response) during the actual spasm.
  3. Neurodevelopmental Plateau or Regression: Loss of previously acquired developmental milestones (visual tracking, social smiling, head control, rolling).
• Etiology: Underlying structural, genetic, or metabolic etiology in 60–70% of cases, including Tuberous Sclerosis Complex (TSC1/TSC2), perinatal hypoxic-ischemic encephalopathy, focal cortical dysplasia, Trisomy 21, or inborn errors of metabolism.
• First-Line Pharmacotherapy:
  • Hormonal Therapy: High-dose oral Prednisolone (40–60 mg/day) or intramuscular Adrenocorticotropic Hormone (ACTH) is the primary first-line therapy for non-tuberous sclerosis etiologies.
  • Vigabatrin (irreversible GABA-transaminase inhibitor): The unequivocal first-line therapy of choice in Tuberous Sclerosis Complex, achieving spasm cessation in >80% of patients.

  • Warning

  • Vigabatrin Visual Toxicity: Permanent visual-field loss is a serious risk. Arrange baseline and regular specialist ophthalmic assessment using age-appropriate methods. Infants cannot perform reliable perimetry; ERG/OCT testing is individualized rather than mandatory for every infant.

3. Self-Limited Epilepsy with Centrotemporal Spikes (SeLECTS / Benign Rolandic Epilepsy)

• Epidemiology: The most common focal childhood epilepsy (15% of all pediatric epilepsies). Onset between 3 and 12 years (peak 7–8 years), with normal baseline neurodevelopment and intelligence.
• Semiology: Characteristic nocturnal or early-morning focal motor and somatosensory seizures occurring during sleep or upon waking:
  • Unilateral hemifacial twitching or tonic contraction.
  • Paresthesia/numbness of the tongue, cheek, or gums.
  • Inability to speak (speech arrest) despite preserved consciousness and comprehension.
  • Excessive salivation and drooling, accompanied by guttural gurgling sounds.
  • May evolve into a generalized tonic-clonic seizure during sleep.
• EEG Hallmark: Broad, high-amplitude, diphasic sharp waves localized over the centrotemporal (Rolandic) regions, with a normal background. The epileptiform discharges are characteristically activated and markedly accentuated during non-REM sleep.
• Prognosis and Management: Excellent prognosis; seizures remit spontaneously in adolescence (usually by age 15–16) without residual neurological or cognitive deficits. If seizures are infrequent, nocturnal, and non-disruptive, pharmacotherapy is often omitted. If daytime seizures or significant parental anxiety warrant medication, Levetiracetam or Sulthiame is preferred.

4. Juvenile Myoclonic Epilepsy (JME / Janz Syndrome)

• Epidemiology: Onset in adolescence between 12 and 18 years. Accounts for 5% to 10% of all epilepsies.
• Semiology:
  • Myoclonic Jerks: Rapid, shock-like, involuntary muscle contractions of the neck, shoulders, and upper limbs (causing patients to drop cups, smartphones, or hairbrushes), occurring characteristically within 1 to 2 hours of waking in the morning.
  • Generalized Tonic-Clonic Seizures (GTCS): Experienced by >90% of patients, frequently preceded by a cluster of myoclonic jerks.
  • Absence Seizures: Present in approximately 30% of cases.
  • Triggers: Sleep deprivation, sudden awakening, psychological stress, alcohol consumption, and photic stimulation (flickering lights/video games).
• EEG Hallmark: Generalized 4 to 6 Hz irregular polyspike-and-wave discharges, frequently accentuated by photic stimulation.
• Long-Term Management: JME requires lifelong treatment, as seizure relapse occurs in >80% of patients upon medication withdrawal.
• Medication Selection:
  • First-Line: Levetiracetam or Sodium Valproate.

  • Caution

  • Valproate Teratogenicity in Females: Sodium Valproate carries a severe risk of major congenital malformations (~10%, including neural tube defects and cardiac anomalies) and neurodevelopmental disorders/autism spectrum conditions (30% to 40%). Under European Medicines Agency (EMA) regulations, valproate is strictly restricted in female adolescents and women of childbearing potential unless no suitable alternative exists and a pregnancy prevention programme is established. Levetiracetam or Lamotrigine is the preferred first-line agent in adolescent girls.

---

Overview of Pediatric Antiseizure Medications (ASMs)